PTO/SB/08b(10-07)

Approved for use through 10/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork. Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Sheet 1

(Use as many sheets as necessary) of 6

		Complete ii raiowii		
	Application Number	10/660,131		
	Filing Date	September 11, 2003		
	First Named Inventor	David H. Munn et al.		
	Art Unit	1647		
	Examiner Name	Regina M. DeBerry		
٦	Attorney Docket Number	M0351-287806		

U.S. PATENT DOCUMENTS							
Examner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Releva		
initials *	No."	Number - Kind Code ² (if known)	MM-DD-YYYY	GIRC DIAGING II	Passages or Relevant Figures Appear		
RMD	1.	US - 2003/0194803 A1	10-16-2003	Munn et al.			
- 1	2	US- 2006/0292618 A1	12-28-2006	Mellor et al.			
RMD	3	US- 2007/0048769 A1	03-01-2007	Mellor et al.			
		_					

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite Foreign Patent Document Publicate	Publication	Name of Palentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.,	Country Code ³ - Number ⁴ - Kind Code ⁵ (# known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
RMI	4	WO 1999/29310	06-17-1999	Medical College of Georgia Res (Abstract)		
RN	ID 5.	WO 2000/66764	11-09-2000	Ludwig Institute for Cancer Research		
_						
		 				

Examiner Signature	/RMD/ 12/03/2007 (12/03/2007)	Date Considered	

EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not "EXAMINEE Initial of interview consistent, whether or not clation is in contomasce with MMPE 605 Days tree through cultation it not incorrectly controlled to the controlled of the controlled o

This callection of information is required by 27 CFR 197 and 198. The obtained is required to obtain or texts a benefit by the public which is to life (and by the USFY) to process, an explication Confidentially is governed by 58 U.S.C. 129 and 37 CFR 11.4 This collection is estimated to stake 2 having to complete, including aghiering, preparing, and submitting the completed application from to the USFYC. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete the from andres respectives for evidency life burden, above the sent to the Cheel Homestern Officer, U.S. Patent and Trademark Office, U.S. Depertment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet 2

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

Complete if Known						
Application Number	10/660,131					
Filing Date	September 11, 2003					
First Named Inventor	David H. Munn et al.					
Art Unit	1647					
Examiner Name	Regina M. DeBerry					
Attorney Docket Number	M0351-287806					

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RMD	BABAN et al., "A Minor Population of Splenic Dendritic Cells Expressing CD19 Mediates IDO-Dependent T Cell Suppression Via Type 1 IFN Signaling Following 87 Ligation," International Immunology, 2005 17(7): 909-919		
 BJORCK et al., "Isolation and characterization of plasmacytoid dendritic cells from Fit3 ligand and granulos macrophage colony-stimulating factor-treated mice" <i>Blood</i>, 2001, <u>99</u>(13): 3520-3526. 		BJORCK et al., "Isolation and characterization of plasmacytoid dendritic cells from Fit3 ligand and granulocyte- macrophage colony-stimulating tactor-treated mice" Blood, 2001, 99(13): 3520-3526.	
	8	BORRAS et al., "Identification of Both Myeloid CD11c and Lymphold CD11c Dendritic Cell Subsets in Cord Bood," British Journal of Haematology, 2001, 113, 925-931.	_
	9	CADY et al., "1-Methyl-DL-tryptophan, beta-(3berzoluranyl)-DL-atanine (the oxygen analog of tryptophan), and beta-3-benzol(bithenyl-DL-atanine) for indolearmine 2,3-dioxygenase, "Archives of Biochemistry and Biophysics, 1991, 291(27):326-33(Abstract).	
	10.	CHAPMAN et al., "Pharmacologically active benzo bithiophene derivatives. VIII Benzo bithiophene analogs of tryptophan and alphamethythyptophan, and some of their 5-substituted derivatives," Journal of the Chemical Society, Section C: Organic Chemistry, 1989, No. 14: 1855-1858 (labstract).	
Patients with Recurrent Ewing Sarcoma and Alveolar Rhabdomyosarcoma. An Inter-Institute NIH Stud		DAGHER et al., "Pitot Trial of Tumor-Specific Peptide Vaccination and Continuous Infusion Intarteukin-2 In Patients with Recurrent Ewing Sarcoma and Alveolar Rhabdomyosarcoma. An Inter-Institute NIH Study." Med. Pediatr. Opiol., 2002, 39: 158-164	
	12	European Petern Office Supplementary Pedal European Search Report Application No. ER 02 80.7233 Date of Completion of the Search October 19, 2005, 5 pages. considered do not prin	ıt
	13	FRIBERG et al., *Indoleamine 2,3-Dioxygenase Contributes to Tumor Cell Evasion of T Cell-Mediated Rejection,* Int. J. Cancer, 2002, 101 151-155.	
	14	FRIBERG et al., "Indoteamine 2,3-dioxygenase (IDO) protects established tumors from T cell mediated rejection," Proc. Amer. Ass. Cancer Res. Ann. Meet., 2000, No. 714, page 112 (Abstract)	
	15	FRUMENTO at al., "Inhibition of T call prohieration by the purified enzyme indoleranine 2,3-dioxygenase." Human Immunology, The European Federation for Immunogenetics 14" Annual Conference, April 4-7, 2000, 61, page 5140 (Abstract)	
	16	GROHMANN et al., "IFN-y Inhibits Presentation of a Tumor-Seit Peptide by CDBa- Dendrific Cets Via Potentiation of the CDBa+ subset" Journal of Immunology, 2000, 165(3): 1357-1363.	
	17	HWU et al., "Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation" J. Immunol., 2000, 164, 3596-3599	
RMD	18	International Search Report for FIGURE 1000-1000 Most April 19, 2002 makes September 0, 2002 Considered do not print	

Examiner /RMD/ 12/03/2007 (12/03/2 007)	Date Considered
---	-----------------

*EXAMINER. Initial if reference considered, whether or not cristion is in conformance with MPEP 609. Draw line through diletion if not in conformance and not considered.

"Exchanged this air research consequent, whether or followers in continuous with water too; these test integrations from communications and in continuous."

Application should be interested to the continuous and the contin

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 10/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

September 11, 2003

10/660,131

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Application Number

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449B/PTO

Sheet

Filing Date First Named Inventor David H. Munn et al. Art Unit 1647 (Use as meny sheets as necessary) Examiner Name Regina M. DeBerry 3 of Attorney Docket Number M0351-287806

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RMD	19	LEE et al., "Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma," Laboratory Investigation, 2003, 33(10) 1457-1466.	
	20	MELLOR et al., "Extinguishing Maternal Immune Responses during Pregnancy: Implications for Immunosuppression." Seminars in Immunology, 2001, 13(4): 213-218.	
	21	MELLOR et al., "Tryptophan catabolism and Ticell tolerance immunosuppression by starvation?" Immunology Today, 1999. 20 469-473	
	22	MELLOR et al., "Tryptophan catabolism prevents maternat T cells from activating fethal anti-fetal immune responses," J. Reprod. Immunol., 2001, 52(1-2): 5-13.	
	23	MELLOR et al., "HLA-G transgenic mice." J. Reprod. Immunol., 1999, 43: 253-261.	
	24	MSLLOR et al., "Immunology at the maternal-fetal interface," Ann. Rev. Immunol., 2000, 18: 367-391.	
	25	MELLOR et al. "IDO expression by dendritic cells' tolerance and tryptophan catabolism" Nat. Immunol. Rev., 2004. <u>4</u> 762-774	
	26	MUNN et al. "Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells," Journal of Immunology, 2004, 172: 4100-4110.	
	27	MUNN et al., "Dendritic Cells Have the Option to Express IDO-Mediated Suppression or Not," Blood, 2005, 105(6), 2618.	
	28	MUNN et al., "Macrophage inhibition of T cell activation via depletion of tryptophan," <i>Blood</i> , 1998, <u>48-IV</u> , (Abstract).	
	29	MUNN et al., "Potential Regulatory Function of Human Dendrific Cetts Expressing Indoleamine 2,3-Dioxygenase." Science, 2002, 297: 1867-1870	
	30	MUNN et al. "Regulation of T cell activation by macrophage (Mivariant phi)-mediated tryptophan (TRP) depletion," FASEB Journal, 1998, 12: page A276 (Abstract)	
	31	MUNN et al. "Tolerogenic Antigen-Presenting Celts," Ann. NY. Acad. Sci., 2002 961, 343 345	
	32	OSUGI et al., "Myeloid Blood CD11c+ Dendritic Cells and Monocyte-Derived Dendritic Cells Differ in their Ability to Stimulate T Lymphocytes." Blood. 2002, 100(8): 2858-2866.	
RMD	33	PACANOWSK1e1 al., "Reduced blood CD123" (lymphoid) and CD11c" (myeloid) dendrific cell numbers in primary HIV-1 infection" Blood, 2001. 98(10): 3016-3021.	

Examiner /RMD/ 12/03/2007 (12/03/20	Date Considered
-------------------------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered.

EXAMENT. Initial 1 reference considered, whether or not obtains in conformance with MPEP 600. Once the through obtain it not in conformance and not considered. Include cody of this form with real communication to applicate.

*Applican's unique cations exequated by CPCT 18.03. The intermedians required by the public which is not like public which is not given to property and applications. Confedentially is given more by SSI SSI. 22.22 and 37 CPT 18.14. The confection is permitted to their Desire by CPCT 19.03. The intermedians required by CPCT 19.03. The confedence is permitted to their Desire by CPCT 19.03. The confedence is permitted to their Desire by CPCT 19.03. The confedence is permitted to their Desire by CPCT 19.03. The confedence is permitted to their Desire by CPCT 19.03. The confedence is permitted to their Desire by CPCT 19.03. The confedence is permitted to their Desire by CPCT 19.03. The confedence is permitted to the CPCT 19.03. The confedence is permitted by CPCT 19.03. The confedence is the confedence is permitted by CPCT 19.03. The

Approved for use through 10/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons a

	Substitute for form 1 449B/PTO		Complete if Known
	NEODMATION DICOLOGUE	Application Number	10/660,131
NFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	September 11, 2003
	First Named Inventor	David H. Munn et al.	
		Art Unit	1647
	(Use as many sheets as necessary)	Examiner Name	Regina M. DeBerry
Ĺ	Sheet 4 of 6	Attorney Docket Number	M0351-287806

NON DATENT LITERATURE DOCUMENTS

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, diy and/or country where published.	T ²	
RMD	34	PETERSON et al., "Evaluation of functionalized tryptophan derivatives and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase," Medicinal Chemistry Research, 1994, 3(8): 531-544 (Abstract).		
	35	POTULA et al , "Inhibition of Indoleamine 2,3-Dioxygenase (IDO) Enhances Elimination of Virus-Infected Macrophages in an Animal Model of HIV-1 Encephalitis," Blood, 2005, 108(7), 2382-2390		
	36	REDDY et al., "A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells" <i>Blood</i> , 1997, <u>90</u> (9): 3640-3646.		
	37	ROMANI et al., "Generation of mature dendritic cells from human blood" Immunol, Meth., 1998, 198: 137-151.		
	38	SOUTHAN et al , "Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase." Medicinal Chemistry Research, 1996, §(5): 343-352 (Abstract).		
	39	TAN et al., "Creation of Tolerogenic Human Dendritic Cells via Intracellular CTLA4: A Novel Strategy with Potential in Clinical Immunosuppression," <i>Blood</i> , 2005, <u>108</u> (9), 2936-2943.		
	40	TAN et al., "Modulation of human dendritic cell function following transduction with viral vectors; impications for gene therapy," American Society of Hematology, Blood First Edition Paper, prepublished online January 25, 2005.		
	41	TERNESS et al., "Regulation of Human Auto-and Alloreactive T Cells by Indoleamine 2,3-Dioxygenase (IDO)- Producing Dendritic Cells. Too Much Ado about IDO?" Blood, 2005, 105(6): 2480-2486		
	42	TERNESS et al., "The Immunoregulatory Role of IDO-Producing Dendritic Cells Revisited," Trends in Immunology, 2006, 27 68-73.		
	43	YOSHIDA et al, "Tryptophan Degradation in Transplanted Tumor Cells Undergoing Rejection," Journal of immunology, 1988, 141(8): 2819-2823.		
	44	Office Action mailed 08/13/2007 for U.S. Patent Application Senial No. 10/121,909. Considered do not print		
	45	Response to Non-Fifte Office Action sent to the USPTO on 05/15/2007 for U.S. Patent Application Serial No. 10/121,909	not p	rint
	46	Office Action marked 11/18/2006 for U.S. Patent Application Serial No. 10/121,909 Considered do n	ot pr	int
	47	Election and Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO on 08/24/2006 or U.S. Patent Application Response sent to the USPTO of USPTO or U.S. Patent Application Response sent to the USPTO of USPTO or U.S. Patent Application Response sent to the USPTO of USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent to the USPTO or U.S. Patent Application Response sent	- 1	
RMD	48	Office Action (Restriction) mailed 07/13/2006 for U.S. Patent Application Secial No. 10/12/1903 sidered d	o not	prin

|--|

^{*}EXAMINER- Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through distion if not in conformance and not considered.

Approved for use through 10/30/2007 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO			Complete if Known		
NEO	DIATION DI	CCI OCUPE	Application Number	10/660,131	
	RMATION DI		Filing Date	September 11, 2003	
STAT	FEMENT BY .	APPLICANT	First Named Inventor	David H. Munn et al.	
			Art Unit	1647	
(Use as many sheets as necessary)			Examiner Name	Regina M. DeBerry	
Sheet	5 0	f 6	Attorney Docket Number	M0351-287806	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), itile of the item (book, magazine, journat, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	
RMD	49	Amendment and Response to Office Action Pursuant to 37 C.F.R. § 1.114 (with Request for Continued axamination) sent to the USPTO on 04/30/2006 for USP Page Application Sergial No. 10/121,809.	
	50	Advisory Action mailed 04/09/2006 tor U.S. Patent Application Serial No. 10/121,909 considered do not print	
	51	Amendment and Response to Office Apilion sent to the USPTO on 03/22/2006 U.S. Patent Application Serial No. 10/121,909	
	52	Office Action maked 12/22/2005 for U.S. Patent Application Serial No. 10/121,909 Considered do not print	
	53	Amendment and Response to Office Action sent to the USPTO on 09/28/2006 for U.S. Patent Application Serial No 10/121,909 Considered do not print	
	54	Office Action mailed 06/28/20/5 for U.S. Patent Application Serial No. 10/121,909.	
	55	Election and Response sent to the USPTO on 04/18/2005 for 0.5 Patent Application Serial No. 10/121,909. Considered do not print	
	56	Office Action (Restriction) mailed 03/17/2005 for U.S. Patent Application Serial No. 10/12/309. considered do not print	
	57	Preliminary Amendment sent to the USPTO on 04/12/2002 for U.S. Patent Application Serial No. 10/121,993 CONSIDERED do not print	
	58	Australian Patent Office on 11/12/2004 for Australian Patent Office on 11/12/2004 for Australian Patent Application No 2002307243. considered do not prin	
	59	Australia Examiner's First Report mailed 07/04/2007 for Australian Patent Application No 2002307243. considered do not print	
	60	Australia: Response to Examiner's First Report sent to the Australian Patent Office on 08/14/2007 for Australian Patent Application No. 2002307243. considered do not print	
	61	Canada Office Action mailed 05/09/2007 for Canadian Patent Application No. 2,483,451. considered do not print	
RMD	62	Canada: Response to Office Action sent to the Canadian Patent Office on 10/1/2007 for Canadian Patent Application No. 2,483,451 CONSIDERED do not print	

Examiner Signature	/RMD/ 12/03/2007 (12/03/2007)	Date Considered	
SYAMMED INCO	I reference considered subother or not estable as in conformance with	MPER 609 Drew log t	brough relation if not in conformance and concominged

"EXAMALE! These at inflements considered, whether or not colorin an incohorance with MREP 600. Down in through colorin in not normatice and not considered.

"Application" upons paid to deposition inflement (political). Application is based to deposition inflement (political). Application is provided to deposition inflement (political). Application is provided to deposition inflement (political). Application is provided to deposition inflement (political). Application or retains a sorted by the public which is to list end by the USFTO for process) are substituted to a complete deposition from the USFTO. The set Way applicating from the antifoldation (political) commission for the complete deposition from the USFTO. The set Way applicating from the ordination of the process of the set way application from the antifoldation of the commission of the process of the set way application from the antifoldation of the process of the set way application from the antifoldation of the process of the set way application from the antifoldation of the process of the set way application from the antifoldation of the process of the set way application from the antifoldation of the process of the process of the set way application from the antifoldation of the process of the pro

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b(10-07)

Approved for use through 10/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449B/PTO		Complete if Known				
NEO	DIATION	DIC.	OL OCUPE	Application Number	10/660,131	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	September 11, 2003	
			PPLICANT	First Named Inventor	David H. Munn et al.	
				Art Unit	1647	
(Use as many sheets as necessary)			necessary)	Examiner Name	Regina M. DeBerry	
Sheet	6	of	6	Attorney Docket Number	M0351-287806	

Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) the item (book, magazine, iousmal, sorial, symposium, catalog, act), date, page(s), volum number(s), publisher, city and/or country where published. 63	tion No. 02 tion No. 02 tice on not p	
Section Sect	fice on not p	
1/22/2006 for Ebrush Plane House Charlotte Commission of Publication No. 0267 208 5-2406 Considered do Considered do Considered do Considered Consi	not p	
RMD 66 European Search Report for Application No. EP 02 807 233 8-2405, mailed February 10, 2006.	prin	:
RMD		
	do not	pri

Examiner Signature	/RMD/ 12/03/2007 (12/03/240 Considered	

^{**}EXAMINER: Initial of relevence considered, whether on not creation in conformance with MEEP 090. These five through calculation from in conformance and mean recognition of the conformance and meaning the conformance and Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.